Vanguard Capital Management Establishes 5% Stake in Ligand Pharmaceuticals Inc

Vanguard Capital Management LLC filed a Schedule 13G on May 1, 2026, reporting a new 5.0% ownership stake in Ligand Pharmaceuticals Inc (LGND). As of the event date of March 31, 2026, the firm beneficially owns 997,637 shares of common stock. This position represents a significant increase from a previous ownership of 0.0%, establishing Vanguard as a major institutional holder. The filing indicates that Vanguard exercises sole dispositive power over all 997,637 shares, while holding sole voting power over 149,548 shares. The securities were acquired in the ordinary course of business and are not held for the purpose of influencing or changing the control of the issuer. The reported holdings include shares managed by various Vanguard affiliates, such as Vanguard Asset Management Limited and Vanguard Global Advisers, LLC. This passive investment reflects Vanguard's expanded footprint in the pharmaceutical sector through its managed funds and accounts.